Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Fenaux P, et al. Among authors: cluzeau t. N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892. N Engl J Med. 2020. PMID: 31914241 Free article. Clinical Trial.
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases.
Zakine È, Papageorgiou L, Bourguiba R, Mekinian A, Terrier B, Kosmider O, Hirsch P, Jachiet M, Audia S, Ardois S, Adélaïde L, Bigot A, Duriez P, Emile JF, Lazaro E, Fayard D, Galland J, Hié M, Humbert S, Jean A, Kostine M, Lacombe V, Le Guenno G, Lobbes H, Magy-Bertrand N, Marianetti-Guingel P, Mathian A, Outh R, Saillard C, Samson M, Vial G, Bouaziz JD, Moguelet P, Chasset F; National French VEXAS Study Group (NFVS). Zakine È, et al. J Am Acad Dermatol. 2023 Apr;88(4):917-920. doi: 10.1016/j.jaad.2022.10.052. Epub 2022 Nov 5. J Am Acad Dermatol. 2023. PMID: 36343774 No abstract available.
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.
Walczak P, Choquet S, Dantal J, Boutboul D, Suarez F, Baron M, Morel V, Cluzeau T, Touati M, Elias M, Bachy E, Nicolas-Virelizier E, Houot R, Venton G, Jacquet C, Moles-Moreau MP, Jardin F, Durot E, Balegroune N, Ecotiere L, Guieze R, Kamar N, Ysebaert L, Couzi L, Gonzalez H, Roulin L, Ou K, Caillard S, Zimmermann H, Trappe RU, Roos-Weil D. Walczak P, et al. Among authors: cluzeau t. Haematologica. 2023 Oct 1;108(10):2814-2819. doi: 10.3324/haematol.2022.282297. Haematologica. 2023. PMID: 36891749 Free PMC article. No abstract available.
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: cluzeau t. Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15. Leukemia. 2011. PMID: 21494260
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS). Thépot S, et al. Among authors: cluzeau t. Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6. Am J Hematol. 2014. PMID: 24375487 Free article.
Azacitidine for the treatment of relapsed and refractory AML in older patients.
Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C. Itzykson R, et al. Among authors: cluzeau t. Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24. Leuk Res. 2015. PMID: 25524177 Clinical Trial.
[Management of myelodysplastic syndromes].
Duchmann M, Fenaux P, Cluzeau T. Duchmann M, et al. Among authors: cluzeau t. Bull Cancer. 2015 Nov;102(11):946-57. doi: 10.1016/j.bulcan.2015.07.007. Epub 2015 Sep 26. Bull Cancer. 2015. PMID: 26410692 Review. French.
123 results